Non Squamous Non Small Cell Lung Cancer clinical trials

Explore recruiting non squamous non small cell lung cancer clinical trials.

Recruiting non squamous non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Squamous Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer

Spain, Romania, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Hungary, Romania, Spain, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Romania, Germany, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Italy, Belgium, Spain, Portugal

Phase II and Phase III (Integrated) EU CTIS Study details

BEAMION Lung-2: A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

Belgium, Sweden, Italy, Netherlands, France, Portugal +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Squamous Non Small Cell Lung Cancer trials by city

Non Squamous Non Small Cell Lung Cancer in Toronto Non Squamous Non Small Cell Lung Cancer in Vancouver Non Squamous Non Small Cell Lung Cancer in Montreal Non Squamous Non Small Cell Lung Cancer in Calgary Non Squamous Non Small Cell Lung Cancer in Edmonton Non Squamous Non Small Cell Lung Cancer in Ottawa Non Squamous Non Small Cell Lung Cancer in Winnipeg Non Squamous Non Small Cell Lung Cancer in Quebec City Non Squamous Non Small Cell Lung Cancer in Hamilton Non Squamous Non Small Cell Lung Cancer in Kitchener Non Squamous Non Small Cell Lung Cancer in London Non Squamous Non Small Cell Lung Cancer in Halifax Non Squamous Non Small Cell Lung Cancer in New York Non Squamous Non Small Cell Lung Cancer in Los Angeles Non Squamous Non Small Cell Lung Cancer in Chicago Non Squamous Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease